Egetis Therapeutics AB (LTS:0ABW) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0ABW Egetis Therapeutics AB LTS:0ABW
58 GF Score
Price kr6.29
GF Value kr5.62
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0ABW vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egetis Therapeutics AB Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Short Percentage of Float falls into.


LTS:0ABW
58GF Score
Egetis Therapeutics AB LTS:0ABW
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr6.29 is trading 11.9% above its estimated GF Value™ of kr5.62. GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.

Key valuation signals for LTS:0ABW:

  • Short Percentage of Float:
  • GF Value™: kr5.62 vs. price of kr6.29 (11.9% above fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
58GF Score

Get the complete analysis for LTS:0ABW

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.29
Price
kr5.62
GF Value